Anti-Infectives 2006

 Ceftobiprole

• Appelbaum PC. MRSA-the tip of the iceberg. Clin Microbiol Infect. 2006 Apr;12 Suppl 2:3-10. Review.
• Bogdanovich T, Clark C, Ednie L, Lin G, Smith K, Shapiro S, Appelbaum PC. Activities of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother. 2006 Jun;50(6):2050-7.
• Chambers HF. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clin Microbiol Infect. 2006 Apr;12 Suppl 2:17-22. Review.
• Denis O, Deplano A, Nonhoff C, Hallin M, De Ryck R, Vanhoof R, De Mendonca R and Struelens MJ. In Vitro Activities of Ceftobiprole, Tigecycline, Daptomycin, and 19 Other Antimicrobials against Methicillin-Resistant Staphylococcus aureus Strains from a National Survey of Belgian Hospitals. Antimicrob Agents Chemother. 2006 Aug;50(8):2680–5.
• Livermore DM. Can β-lactams be re-engineered to beat MRSA? Clin Microbiol Infect. 2006 Apr;12 Suppl 2:11-6. Review.
• Rouse MS, Hein MM, Anguita-Alonso P, Steckelberg JM, Patel R. Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Diagn Microbiol Infect Dis. 2006 Aug;55(4):333-6.
  

44th Annual Infectious Diseases of America IDSA Meeting, October 2006

• P-362 / Comparison of Ceftobiprole (BPR) and Vancomycin (VAN) as Treatment of Complicated Skin and Skin Structure Infections (cSSSI) Caused by Panton-Valentine Leukocidin (PVL) Positive Staphylococci. Amsler K, Jacobs M, Bush K, Zhang W, Strauss RS, Noel GJ.
• P-138 / The Safety and Efficacy of Ceftobiprole (BPR) as a Treatment of Complicated Skin and Skin Structure Infections (cSSSI) Caused by Methicillin-Resistant Staphylcococcus aureus (MRSA). Noel GJ, Pypstra R, Strauss RS.
• P-359 / In Vivo Activity of Ceftobiprole in a Staphylococcal Murine Skin Infection Model. Fernandez J, Hilliard JJ, Zhang W, Melton JL, Abbanat D, Santoro CM, Flamm RK, Bush K.
• P-198 / In vivo Anti-pseudomonal Activity of Ceftobiprole. Hilliard JJ, Zhang W, Melton JL, Fernandez J, Flamm RK, Bush K.
• P-192 / In vivo Anti-staphylococcal Activity of Ceftobiprole. Hilliard JJ, Fernandez J, Melton JL, Zhang W, Flamm RK, Bush K.
• P-286 / Ceftobiprole In vitro Interactions with Doripenem, Levofloxacin or Colistin Against Pseudomonas aeruginosa, Acinetobacter baumanii, and Fluoroquinolone-Resistant Escherichia coli. Foleno B, Wira E, Bush K, Flamm RK.
• P-247 / The Comparative In-vitro Activity of Ceftobiprole Against 251 Aerobic and 192 Anaerobic Strains Isolated From Diabetic Foot Infections. Citron DM, Goldstein EJC, Merriam CV, Warren YA, Tyrell KL, Fernandez HT.

46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, September 2006

• L-1212 / Successful Treatment of Complicated Skin Infections (cSSSI) Due to Staphylococci, Including Methicilin-Restitant Staphylococcus Aureus (MRSA) with Ceftobirpole. Noel GJ, Strauss RS, Pypstra R.
• K-0769 / Frequency of Panton-Valentine Leukocidin (PVL) in Staphylococcal Isolates in Latvian Patients with Complicated Skin and Skin Structure Infections (cSSSI). Krievens D, Baldode A, Zeng W, Strauss RS.
• E-0117 / Susceptibilities of Most Prevalent Enterobacteriaceae-Species to Ceftobiprole: Results of the Antimicrobial Resistance Surveillance Study of the Paul Ehrlich Society for Chemotherapy, 2004. Kresken M, Hafner D.
• K-0772 / Association Between Panton Valentine Leukocidin and Oxacillin Resistance in Staphylococcus Aureus in Isolates From an International Study of Complicated Skin and Skin Structure Infections. Jacobs MR, Amsler K, Bajaksouzian S, Windau A, Bwanga F, Heep M, Strauss RS, Busch K. 
• E-0115 / In Vitro Activity of Ceftobiprole Tested Against a Recent Collection of North American Pseudomonas Aeruginosa. Fritsche TR, Sader HS, Jones RN.
• E-0114 / Spectrum and Potency of Ceftobiprole Tested Against Staphylococci and Streptococci Recovered from Patients in Latin America (2003-2005). Fritsche TR, Sader HS, Jones RN.
• E-0120 / Anti-Anaerobic Activity of Ceftobiprole Compared to Other Agents. Ednie LM, Shapiro S, Appelbaum PC.
• C1-0933 / Binding of Ceftobiprole and Comparators to Penicillin-Binding Proteins in Pseudomonas Aeruginosa. Davies TA, Shang W, Flamm RK, Busch K. 
• E-0112 / Baseline Surveillance Profiles of Ceftobiprole (BPR) Activity Against Enterobacteriaceae and P. Aeruginosa (PA). Brown NP, Jones ME, Draghi DC, Aranza MK, Murfitt K, Thornsberry C, Sahm DF. 
• B-1125 / Evaluation of Ceftobiprole in a Mouse Model of Peritonitis Due to Enterococcus Faecalis Including a Bla+ Strain. Arias CA, Singh KV, Murray BE.
• E-0116 / Ceftobiprole Activity Against Baseline Pathogens From a Complicated Skin and Skin Structure Infection Clinical Trial. Amsler KM, Bush K, Strauss R. Bajaksouzian S, Windau A, Heep M, Jacobs MR.
• A-1943 / Pharmacokinetics (PK) of Multiple Infusions of Ceftobiprole (1000 mg Every 8 hours) in Healthy Volunteers. Schmitt-Hoffmann A, Murthy B, Strauss RS, Pypstra R.
• E-0113 / Profile of Ceftobiprole (BPR) Activity Against Staphylococci and S. Pneumoniae (SP): Results of the 2005-2006 Surveillance Program. Sahm DF, Brown NP, Draghi DC, Crites E, Aranza MK, Murfitt K, Thornsberrry C, Jones ME.
• E-0118 / In Vitro Activity of Ceftobiprole Against Staphylococci Recovered from Patients with Endocarditis. Rouse MS, Nguyen GV, Steckelberg JM, Patel R.
• E-0119 / In Vitro Activity of Ceftobiprole Against Staphylococci Recovered From Patients with Bone and Joint Infection. Rouse MS, Nguyen GV, Patel R, Steckelberg JM.
• A-0628 / Post-antibiotic Effects of Ceftobiprole Against Gram-Positive Organisms. Pankuch GA, Appelbaum PC.

106th American Society for Microbiology General Meeting
ASM, May 2006, Orlando

• A-013 / Binding of Ceftobiprole and Comparators to Penicillin Binding Proteins in Escherichia coli and Streptococcus pneumoniae. Shang W, Davies TD, Page MGP, Karen B.

16th European Congress of Clinical Microbiology and Infectious Diseases
ECCMID, April 2006, Nice

• P-925 / Interactions of ceftobiprole with serine carbapenemases. Queenan AM, Shang W, Bush K.
• P-1524 / Pharmacodynamic profiling of ceftobiprole for the treatment of complicated skin and skin structure infections and nosocomial pneumonia. Lodise TP, Ma L, Pypstra R, Kahn J, Drusano GL, Noel GL.
• P-1386 / Trends in resistance of bacteraemia isolates in the UK and Ireland and current activity of ceftobiprole. Reynolds R, Hope R, BSAC Working Party on Bacteraemia Resistance Surveillance.
• P-1569 / Anti-staphylococcal activity of ceftobiprole in recent clinical trial isolates. Bush K, Strauss R, Amsler K, Heep M, Bajaksouzian S, Windau A, Jacobs M.
• P-1586 / Mechanism of action of ceftobiprole: structural basis for anti-MRSA activity. Lovering A, Danel F, Page MGP, Strynadka NJ.

Isavuconazole

• Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, Brown T, Roehrle M. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006 Jan;50(1):286-93.
• Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, Roehrle M, Beglinger C. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006 Jan;50(1):279-85.
• Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother. 2006 Jan;57(1):135-8.
• Wind M, Spickermann J, Schleimer M, Donzelli M, Gebhardt K, Sturm-Haurany R, Klauer D, Fullhardt P, Schmitt-Hoffmann A. Investigation of low-abundant in vitro metabolites of stable isotope-labelled BAL4815 by accurate mass capillary-LC-ESI-qTof-MS and MS/MS. J Mass Spectrom. 2006 Jul;41(7):903-10.
• Warn PA, Sharp A, Mosquera J, Spickermann J, Schmitt-Hoffmann A, Heep M, and Denning DW. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J Antimicrob Chemother. 2006 Oct, (pre-publication).
• Warn PA, Sharp A, Mosquera J, Spickermann J. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J Antimicrob Chemother. 2006; 58: 1198–1207.

46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, September 2006

• M-1589 / In Vitro Activity of the New Azole BAL4815 and Six Other Antifungal Agents against Candida Bloodstream Isolates. Seifert H, Aurbach U, Stefanik D, Cornely O.

• A-1120 / Dose Response Curves and Dose Fractionation Studies with BAL5887 in a Murine Model of Disseminated Aspergillosis. Warn PA, Sharp A, Denning D.
• M-1588 / In Vitro Activity of Posaconazole Compared with Seven Antifungal Agents against 80 Clinical and 15 Environmental Isolates of Exophiala Dermatitidis. Nweze EI, Curfs-Breuker I, Janssen BGJ, De Hoog GS, Meis JF. 
• M-1587 / In Vitro Activity of the New Azole Isavuconazole BAL 4815 Compared with Six Other Antifungal Agents against 155 Cryptococcus neoformans Isolates from Cuba. Illnait-Zaragozi MT, Curfs-Breuker I, Martinez GF, Fernandez CM, Boekhout T, Meis JF.
• M-1571 / BAL4815, a New Antifungal Agent: Determination of Quality Control Limits for Susceptibility Testing by Methods of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Cuenca-Estrella M, Gomez-Lopez A, Buitrago MJ,  Mellado E, Rodriguez-Tudela JL.

16th Congress of the International Society for Human and Animal Mycology
ISHAM, June 2006, Paris

• A-565 / BAL8557 a Water-soluble Azole in a Phase II Double-blind Esophageal candidiasis Trial: Safety, QT Analysis, and Pharmacokinetics of three Different Dosing Regimens. Schmitt-Hoffmann A, Hardenberg J, Sauer J, Viljoen J, Mitha I, Voiriot P, Heep M.
• A-957 / In Vitro Activity of a New Triazole, BAL8557, Against Histoplasma capsulatum Isolates from Patients who Failed Flucanozole Therapy. Wheat LJ, Connolly P, Smedema M, Durkin M, Goldman M.
• P-0136 / Effect of BAL8557, a Water-soluble Azole Pro-drug, on the Pharmacokinetics of Ciclosporin. Schmitt-Hoffmann A, Roos B, Sauer J, Maares J, Brown T, Spickermann J, Roehrle M, Heep M.
• P-0318 / Effect of Ketoconazole on the Pharmacokinetics of BAL4815 at Steady State after Multiple Oral Daily Doses of BAL8557 (WSA) and Ketoconazole. Schmitt-Hoffmann A, Roos B, Sauer J, Maares J, Spickermann J, Iersel MP, Heep M.
• P-0319 / Effect of Rifampicin on the Pharmacokinetics of BAL4815 at Steady State after Multiple Oral Daily Doses of BAL8557 (WAS) and Rifampicin. Schmitt-Hoffmann A, Roos B, Sauer J, Maares J, Spickermann J, Iersel MP, Heep M.
• P-0320 / Effect of BAL8557, a Water-soluble Azole Pro-drug (WSA), on the Pharmacokinetics of Tacrolimus. Schmitt-Hoffmann A, Roos B, Sauer J, Maares J, Brown T, Spickermann J, Roehrle M, Heep M.
• P-0321 / Effect of BAL8557, a Water-soluble Azole Pro-drug (WSA), on the Pharmacokinetics of S- and R-Warfarin. Schmitt-Hoffmann A, Roos B, Sauer J, Maares J, Brown T, Spickermann J, Allison M, Heep M.
• P-0081 / In Vitro Activity of BAL4815, a New Water-soluble Broad-spectrum Triazole, Against Opportunistic Filamentous and Dimorphic Fungi. Gonzàlez GM and Heep M.
• P-0158 / In Vitro Activity of BAL4815 Against Zygomycetes. Warn P, Sharp A, Denning D.
• P-0556 / Comparison of the In Vitro Activity of BAL4815 and Fluconazole against Cryptococcus neoformans. De la Escalera CM, Aller AI, López-Oviedo E, Martos AI, Romero A, Castro C, Martín-Mazuelos E.
• P-0554 / In Vitro Activity of BAL4815 (a New Azole) against Filamentous Fungi. De la Escalera CM, Aller AI, López-Oviedo E, Martos AI, Romero A, Castro C, Cantón E, Martín-Mazuelos E.

Research

• Freiberg C, Pohlmann J, Nell PG, Endermann R, Schuhmacher J, Newton B, Otteneder M, Lampe T, Häbich D, Ziegelbauer K. Novel bacterial acetyl coenzyme a carboxylase inhibitors with antibiotic efficacy in vivo. Antimicrob Agents Chemother. 2006 Aug;50(8):2707-12.
• Marrer E, Satoh AT, Johnson MM, Piddock LJV, Page MGP. Global transcriptome analysis of the responses of a fluoroquinolone-resistant Streptococcus pneumoniae mutant and its parent to ciprofloxacin. Antimicrob Agents Chemother. 2006 Jan;50(1):269-78.
• Marrer E, Schad K, Satoh AT, Page MGP, Johnson MM, Piddock LJV. Involvement of the putative ATP-dependent efflux proteins PatA and PatB in fluoroquinolone resistance of a multidrug-resistant mutant of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006 Feb;50(2):685-93.
• Sukuru SC, Crepin Th, Milev Y, Marsh LC, Hill JB, Anderson RJ, Morris JC, Rohatgi A, O’Mahony G, Grøtli M, Danel F, Page MGP, Härtlein M, Cusack St, Kron MA, Kuhn LA. Discovering new classes of brugia malayi asparaginyl-tRNA synthetase inhibitors and relating specificity to conformational change. Journal of Computer-Aided Molecular Design 2006; published online: 28 April 2006.